PMID- 11553367
OWN - NLM
STAT- MEDLINE
DCOM- 20020327
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 103
IP  - 5
DP  - 2001 Sep 1
TI  - Clinical experiences with low-molecular weight heparins in pediatric patients.
PG  - 345-53
AB  - The courses of 79 children (2 weeks to 19 years old) treated with two different 
      low-molecular weight heparins (LMWHs)--nadroparin (n=66) and enoxaparin 
      (n=13)--were retrospectively analysed. In 62 patients, LMWHs were given for 
      short-term prophylaxis (1-2 weeks) during immobilization after surgery or trauma. 
      Thirteen children with thromboembolic events received long-term prophylaxis with 
      LMWHs for 2-18 months--six after thrombolytic therapy and seven after therapy 
      with unfractionated heparin (UFH). Because of thromboembolic events, four 
      patients were initially treated with LMWHs. In all patients with short-term 
      prophylaxis, no thrombosis occurred. After thrombolytic therapy, three children 
      had no reocclusion, two had no thrombus apposition and one had complete 
      recanalization. In the seven patients treated with LMWHs after UFH, four had no 
      reocclusion, two had recanalization and one had reocclusion. In all patients 
      receiving LMWHs for initial treatment of thrombosis, no thrombus apposition, but 
      also no recanalization, occurred. For short-term prophylaxis, nadroparin was used 
      independent of the body weight and without determination of anti-factor Xa 
      (anti-FXa) activity. Long-term prophylaxis was given mainly as doses of 45-100 
      anti-FXa U/kg resulting in anti-FXa activities between 0.2 and 0.4 U/ml. For 
      treatment of thrombosis, doses of 200-300 anti-FXa U/kg corresponded to 0.5-1.0 
      anti-FXa U/ml. Side effects--slight gastrointestinal bleeding and temporary 
      reversible hair loss--were seen in two patients. In conclusion, LMWHs proved to 
      be efficacious and safe especially in prophylaxis of thromboembolic events in 
      children.
FAU - Hofmann, S
AU  - Hofmann S
AD  - Department of Pediatrics, University Hospital of Technical University, 
      Fetscherstrasse 74, D-01307 Dresden, Germany.
FAU - Knoefler, R
AU  - Knoefler R
FAU - Lorenz, N
AU  - Lorenz N
FAU - Siegert, G
AU  - Siegert G
FAU - Wendisch, J
AU  - Wendisch J
FAU - Mueller, D
AU  - Mueller D
FAU - Taut-Sack, H
AU  - Taut-Sack H
FAU - Dinger, J
AU  - Dinger J
FAU - Kabus, M
AU  - Kabus M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Nadroparin)
SB  - IM
MH  - Adolescent
MH  - Anticoagulants/*administration & dosage/toxicity
MH  - Child
MH  - Child, Preschool
MH  - Enoxaparin/administration & dosage/toxicity
MH  - Factor Xa Inhibitors
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*administration & dosage/toxicity
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Nadroparin/administration & dosage/toxicity
MH  - Retrospective Studies
MH  - Thromboembolism/drug therapy/prevention & control
MH  - Thrombolytic Therapy
MH  - Thrombosis/drug therapy/prevention & control
MH  - Treatment Outcome
EDAT- 2001/09/13 10:00
MHDA- 2002/03/28 10:01
CRDT- 2001/09/13 10:00
PHST- 2001/09/13 10:00 [pubmed]
PHST- 2002/03/28 10:01 [medline]
PHST- 2001/09/13 10:00 [entrez]
AID - S0049-3848(01)00335-8 [pii]
AID - 10.1016/s0049-3848(01)00335-8 [doi]
PST - ppublish
SO  - Thromb Res. 2001 Sep 1;103(5):345-53. doi: 10.1016/s0049-3848(01)00335-8.